JAK2 and myeloproliferative neoplasm: In addition, the JAK2(V617F) mutation has been associated with Wnt regulatory gene epigenetic silencing in human myeloproliferative neoplasm pathogenesis (Bennemann et al., 2012); and the HDACi givinostat would induce its anticancer effects, at least in part, by selectively targeting cells bearing this mutation (Jenke et al., 2021), suggesting that genetic and epigenetic factors collaborate in the pathogenesis of these HMs.